Addex Therapeutics' stock is up following the regaining of full global rights to key drug assets. This move enhances their pipeline control and potential future revenue streams, signaling increased autonomy and value for the company.
This headline is a significant corporate catalyst for Addex Therapeutics, as regaining full global rights to GABAB positive allosteric modulator assets provides them with complete control over the development and commercialization of these potentially valuable drug candidates. This could lead to increased future revenue potential and a stronger pipeline, justifying the positive stock movement. For Indivior UK, losing these rights could be seen as a negative, as it reduces their potential future pipeline or revenue from these specific assets. The biotechnology sector often sees substantial stock movements based on pipeline developments and intellectual property rights, making this a key event for both companies involved. Traders will likely view this as a long-term positive for Addex, while Indivior's future strategy regarding these assets will be scrutinized.